Targeted Treatment for Infections
Our product candidates may be used both to treat active infections and prophylactically, to prevent infections from occurring.
Our gene therapy platform, AAV-mAb, is designed to make and release proprietary, specific monoclonal antibodies (mAb) against healthcare-acquired and pandemic infections.
Healthcare-acquired viral infections:
- Respiratory syncytial virus
- Influenza and parainfluenza
Healthcare-acquired bacterial infections:
- Clostridium difficile
- Staphylococcus aureus
- Escherichia coli
- Enterococcus faecalis
- Pseudomonas aeruginosa
- Group A Streptococcus
Pandemic infections:
- COVID-19
COMPANY
Avamab Pharma Inc. was founded in 2018 in Calgary, Canada. Our executive and scientific team brings together decades of experience in drug development and taking new therapies to market. Our mission is to develop gene therapies to safely and effectively treat life-threatening infections, including those that have become resistant to existing treatments. To this end, we use our gene therapy platform, AAV-mAb, to make and release proprietary, specific monoclonal antibodies (mAb) against healthcare-acquired and pandemic infections.
How it Works
1
Release Viral Vector
Our product candidates may be used both to treat active infections and prophylactically, to prevent infections from occurring.
2
Produce Antibodies
Target cells are induced to produce neutralizing mAb.
3
Treat Infection
The healthcare-acquired or pandemic infection is treated.
